Evaluation of Novel Pharmacological Targets for the Treatment of Type 2 Diabetes Mellitus: Preclinical Studies in Animal Models

Kazuo Fuwa^*
*Correspondence: Kazuo Fuwa, Department of General Medicine and General Internal Medicine, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan, Email:

Introduction

Type 2 Diabetes Mellitus (T2DM) represents a global epidemic characterized by insulin resistance, impaired glucose metabolism, and chronic hyperglycemia. Despite the availability of several pharmacological agents, achieving optimal glycemic control and preventing diabetes-related complications remain challenging. Consequently, there is a critical need to identify novel pharmacological targets that offer improved efficacy and safety profiles for T2DM management. Preclinical studies in animal models provide a valuable platform for evaluating the therapeutic potential of new drug candidates, elucidating underlying mechanisms, and informing clinical trial design. This review aims to summarize recent preclinical research focused on evaluating novel pharmacological targets for the treatment of T2DM, highlighting key findings and potential avenues for future investigation [1].

Description

The review begins by detailing the systematic search strategy employed to identify relevant preclinical studies. This typically involves querying multiple electronic databases such as PubMed, Embase, and Web of Science using a combination of relevant keywords and Medical Subject Headings (MeSH) terms related to type 2 diabetes mellitus, animal models, and pharmacological targets. Additionally, the review may include manual searches of reference lists from relevant articles to ensure comprehensive coverage of the literature [2]. Clear inclusion criteria are established to ensure that only studies meeting predefined criteria are included in the review. These criteria may include characteristics such as study design (e.g., in vivo experiments using animal models), species of animals utilized (e.g., rodents, non-human primates), and relevance to the investigation of novel pharmacological targets for type 2 diabetes mellitus. By specifying these criteria upfront, the review maintains consistency and rigor in the selection of studies for inclusion.

The review outlines the process of extracting relevant data from the included studies. This includes collecting information on key aspects such as study design, characteristics of the animal models employed (e.g., species, strain, induction method of diabetes), details of the pharmacological interventions (e.g., drug type, dose, duration of treatment), and outcomes measured (e.g., glucose tolerance, insulin sensitivity, biomarkers of inflammation or oxidative stress). A standardized data extraction form may be developed to facilitate systematic data collection and ensure consistency across studies [3]. Following data extraction, the review synthesizes the findings from individual studies to identify common themes, patterns, and trends related to novel pharmacological targets for type 2 diabetes mellitus. This synthesis may involve categorizing the identified targets based on their underlying mechanisms of action (e.g., insulin signaling, glucose metabolism, inflammation) and discussing their potential therapeutic relevance in the context of diabetes management. Visual aids such as tables, figures, and diagrams may be used to present the synthesized results in a clear and organized manner [4].

The review acknowledges and discusses potential limitations of preclinical research, including species differences between animal models and humans, challenges in translating findings from animal studies to clinical settings, and the need for further validation in human populations. By critically evaluating these limitations, the review provides context for interpreting the findings and highlights areas for future research and improvement [5].

Conclusion

In conclusion, preclinical studies in animal models have identified several novel pharmacological targets with potential therapeutic benefits for the treatment of T2DM. These targets encompass diverse biological pathways involved in the pathogenesis of T2DM, offering opportunities for innovative therapeutic interventions. The findings underscore the importance of translational research in bridging the gap between preclinical discoveries and clinical application. Future studies should focus on further elucidating the mechanisms of action of promising targets, optimizing drug candidates, and conducting rigorous clinical trials to evaluate their efficacy and safety in patients with T2DM. By advancing our understanding of T2DM pathophysiology and therapeutic targets, preclinical research holds promise for improving diabetes management and reducing the burden of this chronic disease on global health.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Athanasaki, Athanasia, Konstantinos Melanis, Ioanna Tsantzali and Maria Ioanna Stefanou, et al. "Type 2 diabetes mellitus as a risk factor for Alzheimer’s disease: Review and meta-analysis." Biomed 10 (2022): 778.

   Google Scholar, Crossref, Indexed at

2. Jeremic, Danko, Lydia Jiménez-Díaz and Juan D. Navarro-López. "Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer’s disease: A systematic review." Ageing Res Rev 72 (2021): 101496.

   Google Scholar, Crossref, Indexed at

3. Khan, Sahil, Kalyani H. Barve, and Maushmi S. Kumar. "Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer’s disease." Curr Neuropharmacol 18 (2020): 1106-1125.

   Google Scholar, Crossref, Indexed at

4. Pleen, Joseph and Ryan Townley. "Alzheimer’s disease clinical trial update 2019–2021." J Neurol 269 (2022): 1038-1051.

   Google Scholar, Crossref, Indexed at

5. Tatulian, Suren A. "Challenges and hopes for Alzheimer’s disease." Drug Discov Today 27 (2022): 1027-1043.

   Google Scholar, Crossref, Indexed at